Sciatica - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Sciatica - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Sciatica pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Sciatica: Overview
Sciatica also known as sciatic neuralgia or sciatic neuropathy—is mild to intense low back pain that travels into the left or right leg. This pain can be made worse by certain movements such as twisting, bending, or coughing. Sciatica affects 10 to 40 percent of the population, classically around 40 years of age. Sciatica is caused by compression or irritation of one or more of the five sets of nerve roots in the lower back. Pain from sciatic nerve compression may feel dull, sharp, and/or create a burning sensation. It may also be accompanied by intermittent shocks of shooting pain beginning in the buttock and traveling downward into the back and/or side of the thigh and/or leg (also known as radiating pain).
'Sciatica - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sciatica pipeline landscape is provided which includes the disease overview and Sciatica treatment guidelines. The assessment part of the report embraces, in depth Sciatica commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sciatica collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Sciatica report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sciatica Emerging Drugs
Further product details are provided in the report……..
Sciatica: Therapeutic Assessment
This segment of the report provides insights about the different Sciatica drugs segregated based on following parameters that define the scope of the report, such as:
Sciatica: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sciatica therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sciatica drugs.
Sciatica Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Sciatica - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Sciatica pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Sciatica: Overview
Sciatica also known as sciatic neuralgia or sciatic neuropathy—is mild to intense low back pain that travels into the left or right leg. This pain can be made worse by certain movements such as twisting, bending, or coughing. Sciatica affects 10 to 40 percent of the population, classically around 40 years of age. Sciatica is caused by compression or irritation of one or more of the five sets of nerve roots in the lower back. Pain from sciatic nerve compression may feel dull, sharp, and/or create a burning sensation. It may also be accompanied by intermittent shocks of shooting pain beginning in the buttock and traveling downward into the back and/or side of the thigh and/or leg (also known as radiating pain).
'Sciatica - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sciatica pipeline landscape is provided which includes the disease overview and Sciatica treatment guidelines. The assessment part of the report embraces, in depth Sciatica commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sciatica collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sciatica R&D. The therapies under development are focused on novel approaches to treat/improve Sciatica.
This segment of the Sciatica report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sciatica Emerging Drugs
- STX-015: Sollis Therapeutics
- SP-102: Scilex Holding
Further product details are provided in the report……..
Sciatica: Therapeutic Assessment
This segment of the report provides insights about the different Sciatica drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Sciatica
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Sciatica: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sciatica therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sciatica drugs.
Sciatica Report Insights
- Sciatica Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Sciatica drugs?
- How many Sciatica drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sciatica?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sciatica therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sciatica and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sollis Therapeutics
- Scilex Holding
- Eliem Therapeutics
- Breath of Life International Pharma Ltd
- Kolon Life Science
- SPINETHERA
- STX-015
- SP-102
- ETX 810
- BOL-DP-o-04
- KLS 2031
- SX600
Introduction
Executive Summary
Sciatica: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
STX-015: Sollis Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ETX 810: Eliem Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
KLS 2031: Kolon Life Science
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sciatica Key Companies
Sciatica Key Products
Sciatica- Unmet Needs
Sciatica- Market Drivers and Barriers
Sciatica- Future Perspectives and Conclusion
Sciatica Analyst Views
Sciatica Key Companies
Appendix
Executive Summary
Sciatica: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
STX-015: Sollis Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ETX 810: Eliem Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
KLS 2031: Kolon Life Science
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sciatica Key Companies
Sciatica Key Products
Sciatica- Unmet Needs
Sciatica- Market Drivers and Barriers
Sciatica- Future Perspectives and Conclusion
Sciatica Analyst Views
Sciatica Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Sciatica
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Sciatica
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Sciatica
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Sciatica
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
